Core Insights - Jilin Aodong (000623.SZ) reported a 20.21% year-on-year decrease in operating revenue, amounting to 1.126 billion yuan for the first half of 2025 [1] - The net profit attributable to shareholders increased by 138.44% year-on-year, reaching 1.282 billion yuan [1] - The net profit excluding non-recurring gains and losses was 1.167 billion yuan, reflecting a 43.68% year-on-year growth [1] - The company proposed a cash dividend of 2.00 yuan (including tax) for every 10 shares to all shareholders [1] Revenue Breakdown - The pharmaceutical and chain pharmacy wholesale and retail business generated 1.016 billion yuan, accounting for 90.22% of total operating revenue, which is a 16.31% decrease compared to the same period last year [1] - Traditional Chinese medicine revenue was 686 million yuan, down 21.41% year-on-year [1] - Chemical drug revenue amounted to 143 million yuan, a decline of 6.02% year-on-year [1] - Revenue from chain pharmacy wholesale and retail business was 187 million yuan, showing a slight decrease of 1.07% year-on-year [1]